

A Satellite Symposium at the 2007 Crohn's & Colitis Foundation of America National Research and Clinical Conference – 6th Annual Advances in the Inflammatory Bowel Diseases

EARLY USE OF BIOLOGICS IN CROHN'S DISEASE:

RAMIFICATIONS ON QUALITY OF LIFE,
DISEASE COURSE AND PATIENT SAFETY

A unique panel lecture & discussion including researcher, clinician and patient perspectives

Saturday, December 8, 2007 Aventura, Florida

The Fairmont Turnberry Isle Resort & Club, Garden Room, 5:45pm – 7:05pm

Chair:

Douglas C. Wolf, MD
Atlanta Gastroenterology Associates
Atlanta, Georgia

CONTINUING MEDICAL EDUCATION



Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 1.25 of AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.25 contact hours, CERP A, File number 1207-A016.02.

WHO SHOULD ATTEND

This activity is intended for gastroenterologists, clinical researchers and other persons in the healthcare community with an interest in the treatment and management of patients with inflammatory bowel disease. No specialized knowledge other than a working knowledge of Crohn's disease is necessary for successful participation in this course.

EARLY USE OF BIOLOGICS IN CROHN'S DISEASE:

RAMIFICATIONS ON QUALITY OF LIFE, DISEASE COURSE AND PATIENT SAFETY

A unique panel lecture & discussion including researcher, clinician and patient perspectives

Saturday, December 8, 2007 Aventura, Florida

The Fairmont Turnberry Isle Resort & Club, Garden Room, 5:45pm – 7:05pm

SCIENTIFIC PROGRAM

- 5:45 pm Welcome
- 5:50 pm Improving patient selection for a top-down approach in Crohn's disease
- Research perspective:
Maria T. Abreu, MD
Mount Sinai School of Medicine, New York, New York
- Clinician perspective:
Russell D. Cohen, MD
University of Chicago Medical Center, Chicago, Illinois
- Patient perspective:
Joseph Esposito, PhD
Atlanta, Georgia
- Case study with Audience Response Polling and panel discussion
- 6:15 pm Early intervention with anti-TNF agents in Crohn's disease to maximize patient outcomes
- Research perspective: Maria T. Abreu, MD
Clinician perspective: Russell D. Cohen, MD
Patient perspective: Joseph Esposito, PhD
- Case study with Audience Response Polling and panel discussion
- 6:40 pm Closing the gap in understanding of risk-benefit profiles among patients: Balancing complications of treatment with consequences of under-treatment
- Research perspective: Maria T. Abreu, MD
Clinician perspective: Russell D. Cohen, MD
Patient perspective: Joseph Esposito, PhD
- Case study with Audience Response Polling and panel discussion
- 7:05 pm Closing statement/summary and adjourn

EDUCATIONAL OBJECTIVES

After successful completion of this activity, participants should be able to:

- Improve patient selection for top-down treatment in Crohn's disease
- Identify clinical parameters and molecular biomarkers that may predict an aggressive disease course and long-term response to biologics
- Discuss key outcomes with early biologic intervention and differentiate therapy to specific groups in Crohn's disease
- Balance the potential complications of drug treatment against the consequences of potential under-treatment of patients' disease

CONFERENCE ORGANIZER



4325 Alexander Drive
Alpharetta, Georgia 30022 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

CORPORATE SUPPORT

This symposium is made possible by an unrestricted educational grant from



REGISTRATION

Attendees of this complimentary luncheon symposium must be registered for the **2007 Crohn's & Colitis Foundation of America National Research and Clinical Conference – 6th Annual Advances in the Inflammatory Bowel Diseases**